Rekombinanter C5 (Eculizumab Biosimilar) Antikörper

Produktnummer ABIN7200672

Der Maus Monoklonal Anti-C5 (Eculizumab Biosimilar)-Antikörper wurde für FACS und in vivo validiert. Er ist geeignet, C5 (Eculizumab Biosimilar) in Proben von Human zu detektieren.

Kurzübersicht für Rekombinanter C5 (Eculizumab Biosimilar) Antikörper (ABIN7200672)

Target: C5 (Eculizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser C5 (Eculizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Produktdetails anti-C5 (Eculizumab Biosimilar) Antikörper

Verwendungszweck: Eculizumab Biosimilar, Human C5 Monoclonal Antibody

Spezifität: The monoclonal antibody Eculizumab biosimilar specifically binds to the human C5, the terminal complement component 5.

Produktmerkmale: Recombinant Humanized IgG2 Monoclonal Antibody.

Aufreinigung: Protein A affinity column

Reinheit: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The monoclonal antibody Eculizumab biosimilar was produced in the Eculizumab biosimilar CHO stable cell line.

Isotyp: IgG2, IgG4, kappa

Anwendungsinformationen

Applikationshinweise: ELISA, functional assays such as bioanalytical PK and ADA assays.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Handhabung: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu C5 (Eculizumab Biosimilar)

Target: C5 (Eculizumab Biosimilar)

Substanzklasse: Biosimilar

Hintergrund: Eculizumab, a recombinant humanized anti-C5 (the terminal Complement component 5) monoclonal antibody, selectively targets and inhibits the terminal portion of the complement cascade. Eculizumab is a first-in-class terminal complement inhibitor to treat paroxysmal nocturnal hemoglobinuria (PNH) with excessive destruction of red blood cells (hemolysis). Eculizumab is also the first agent to treat atypical hemolytic uremic syndrome (aHUS) with abnormal blood clots to form in small blood vessels throughout the body, leading to kidney failure, damage to other vital organs and premature death.

The complement immune system destroys and removes foreign particles by the complement cascade triggered by foreign particles. The complement proteins activiated in order create holes or pores in the invading organisms, leading to their destruction. The complement immune system in patients can also destroy healthy cells and tissue, resulting in excessive destruction of red blood cells (hemolysis) or abnormal blood clots to form in small blood vessels throughout the body.

When activated, C5 at a late stage in the complement cascade is involved in activating host cells, thereby attracting pro-inflammatory immune cells, while also destroying cells by triggering pore formation. Eculizumab specifically binds to C5 and inhibits the cleavage of C5 to C5a (a potent anaphylatoxin with prothrombotic and proinflammatory properties) and C5b by the C5 convertase, preventing the generation of the terminal complement complex C5b-9 (which also has prothrombotic and proinflammatory effects). Both C5a and C5b-9 cause the terminal complement-mediated events that are characteristic of PNH and aHUS. By doing so, the normal, disease-preventing functions of proximal complement system are largely preserved, while the properties of C5 that promote inflammation and cell destruction are impeded.